SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Bajaj Healthcare surges on launching antiviral drug ‘Favijaj’

05 May 2021 Evaluate

Bajaj Healthcare is currently trading at Rs. 597.50, up by 14.45 points or 2.48% from its previous closing of Rs. 583.05 on the BSE.

The scrip opened at Rs. 614.40 and has touched a high and low of Rs. 619.00 and Rs. 552.65 respectively. So far 149195 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 619.00 on 05-May-2021 and a 52 week low of Rs. 238.05 on 11-May-2020.

Last one week high and low of the scrip stood at Rs. 619.00 and Rs. 475.00 respectively. The current market cap of the company is Rs. 798.70 crore.

The promoters holding in the company stood at 67.26%, Non-Institutions held 32.74%.

Bajaj Healthcare has launched ‘Favijaj’ (Favipiravir) an antiviral drug used for treating patients suffering from influenza virus and has proved to be effective over COVID patients. The company has received approval from India's drug regulator, to manufacture and market ‘Favijaj’ the oral Favipiravir approved medication in India for the treatment of COVID-19 from May 04, 2021.

‘Favijaj’tablets comprising Favipiravir in different dosage forms is used for the treatment of mild to moderate Covid-19 disease. Favipiravir is an antiviral drug, which has shown potent in vitro activity against severe acute respiratory syndrome of coronavirus.

Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.

Bajaj Healthcare Share Price

348.95 -1.50 (-0.43%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×